-
公开(公告)号：US20100310534A1
公开(公告)日：2010-12-09
申请号：US12679696
申请日：2008-09-15
Applicant: Kfir Oved , Eran Eden , Martin Akerman , Roy Noy , Michal Besser , Yoram Reiter
Inventor： Kfir Oved , Eran Eden , Martin Akerman , Roy Noy , Michal Besser , Yoram Reiter
CPC classification number: G01N33/57484 , G01N33/505 , G01N2800/52
Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28−CD152− signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28−CD152− signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
Abstract translation: 公开了一种确定对癌症治疗的反应性的方法。 该方法包括分析受试者样本中具有CD8 + CD28-CD152特征的肿瘤浸润性淋巴细胞（TIL）的频率，其中具有高于预定水平的CD8 + CD28-CD152特征的TIL频率指示 对癌症治疗的积极反应。 还公开了反映对癌症治疗反应的其他签名。 此外，还公开了基于这些标记治疗癌症的方法。
-
2.发明授权Method of predicting responsiveness to autologous adoptive cell transfer therapy 有权预测自体过继细胞转移治疗反应的方法
公开(公告)号：US08541185B2
公开(公告)日：2013-09-24
申请号：US12679696
申请日：2008-09-15
Applicant: Kfir Oved , Eran Eden , Martin Akerman , Roy Noy , Michal Besser , Yoram Reiter
Inventor： Kfir Oved , Eran Eden , Martin Akerman , Roy Noy , Michal Besser , Yoram Reiter
IPC: G01N33/574 , C12Q1/02 , C12N5/07
CPC classification number: G01N33/57484 , G01N33/505 , G01N2800/52
Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28−CD152− signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28−CD152− signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
Abstract translation: 公开了一种确定对癌症治疗的反应性的方法。 该方法包括分析受试者样本中具有CD8 + CD28-CD152特征的肿瘤浸润性淋巴细胞（TIL）的频率，其中具有高于预定水平的CD8 + CD28-CD152特征的TIL频率指示 对癌症治疗的积极反应。 还公开了反映对癌症治疗反应的其他签名。 此外，还公开了基于这些标记治疗癌症的方法。
-
3.发明申请SIGNATURES AND DETERMINANTS FOR DISTINGUISHING BETWEEN A BACTERIAL AND VIRAL INFECTION AND METHODS OF USE THEREOF 有权用于细菌和病毒感染之间鉴别的标记和决定因素及其使用方法
公开(公告)号：US20110275542A1
公开(公告)日：2011-11-10
申请号：US13090893
申请日：2011-04-20
IPC: C40B40/10 , G01N27/447 , G01N33/573 , C12Q1/02 , G01N33/566
CPC classification number: G01N33/56983 , A61K45/06 , G01N33/569 , G01N33/56911 , G01N2333/4737 , G01N2333/914
Abstract: The present invention provides methods of detecting infection using biomarkers.
Abstract translation: 本发明提供使用生物标志物检测感染的方法。
-
公开(公告)号：US09709565B2
公开(公告)日：2017-07-18
申请号：US13090893
申请日：2011-04-20
IPC: C40B40/10 , G01N33/569 , A61K45/06 , C12Q1/02
CPC classification number: G01N33/56983 , A61K45/06 , G01N33/569 , G01N33/56911 , G01N2333/4737 , G01N2333/914
Abstract: The present invention provides methods of detecting infection using biomarkers. The methods disclosed herein include measuring the expression level of one of more polypeptide determinant in which the alteration of the expression level indicates infection of the patient in a sample of the subject and determining a clinically significant alteration in the level of the one or more polypeptides in the sample, wherein the alteration indicates an infection in the subject. The methods provided herein are for distinguishing between bacterial infection, mixed infection and/or viral infection.
-
公开(公告)号：US20100298166A1
公开(公告)日：2010-11-25
申请号：US12864022
申请日：2009-01-22
Applicant: Uri Alon , Alex Sigal , Ron Milo , Tamar Danon , Ariel Cohen , Naama Geva-Zatorsky , Milana Frenkel-Morgenstern , Lydia Cohen , Natalie Perzov , Eran Eden
Inventor： Uri Alon , Alex Sigal , Ron Milo , Tamar Danon , Ariel Cohen , Naama Geva-Zatorsky , Milana Frenkel-Morgenstern , Lydia Cohen , Natalie Perzov , Eran Eden
CPC classification number: A61K31/4745 , C07K2319/60 , C12N15/62
Abstract: Nucleic acid construct systems are disclosed. The constructs comprise: (i) a first nucleic acid construct comprising a first nucleic acid sequence encoding a first reporter polypeptide linked to an additional nucleic acid sequence capable of inserting the first nucleic acid construct into a genome of a host cell such that an endogenous polypeptide covalently attached to the first reporter polypeptide is expressed in the cell; and (ii) a second nucleic acid construct comprising a second nucleic acid sequence encoding a second reporter polypeptide, linked to an additional nucleic acid sequence capable of inserting in a non-directed manner the second nucleic acid construct into a genome of a host cell such that an endogenous polypeptide covalently attached to the second reporter polypeptide is expressed in the cell, wherein the first reporter polypeptide and the second reporter polypeptide are distinguishable. Cells and cell populations comprising same as well as methods of generating same are also disclosed. In addition, use of the novel construct systems are disclosed for identifying target agents are also disclosed.
Abstract translation: 公开了核酸构建体系。 所述构建体包含：（i）第一核酸构建体，其包含编码与能够将第一核酸构建体插入宿主细胞的基因组的另外的核酸序列连接的第一报道多肽的第一核酸序列， 共价连接到第一报道多肽在细胞中表达; 和（ii）第二核酸构建体，其包含编码第二报告多肽的第二核酸序列，其与能够以非定向方式将第二核酸构建体插入宿主细胞基因组的另外的核酸序列连接， 共价连接到第二报道多肽的内源多肽在细胞中表达，其中第一报告多肽和第二报道多肽是可区分的。 还公开了包含相同的细胞和细胞群以及产生它们的方法。 此外，还公开了用于鉴定目标试剂的新型构建体系的使用。
